The data supports a future FDA submission for PTSD, but no timeline given. Monitor for regulatory updates and peer-reviewed publication. The stock may see near-term momentum on the positive data but lacks a near-term catalyst without a formal FDA submission.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 29 $15.17entry
- T+1 · 5mo ago +2.24%α +1.46% · $15.51
- T+5 · 4mo ago +5.60%α +4.22% · $16.02
- T+20 · 4mo ago +5.27%α +5.55% · $15.97
- T+60 · 8w ago −10.15%α −14.54% · $13.63
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BrainsWay presented positive real-world data showing 83.5% of comorbid PTSD/MDD patients responded to Deep TMS with a 52% mean symptom reduction. However, the therapy is not yet FDA-cleared for PTSD, limiting immediate commercial impact. The data strengthens the clinical evidence base but does not change near-term revenue or regulatory status.
Key Facts
- 83.5% of 462 comorbid PTSD/MDD patients responded to Deep TMS (≥50% symptom reduction).
- Mean PTSD symptom reduction of 52% (PCL-5).
- 66.6% depression response rate, 27.3% remission rate, mean 50% PHQ-9 reduction.
- Deep TMS is not yet FDA-cleared for PTSD; results are from a retrospective, real-world study.
- BrainsWay has three existing FDA clearances: MDD, OCD, and smoking addiction.
Financial Impact
No immediate revenue impact; potential future upside if FDA clearance for PTSD is pursued and obtained.
Risk Factors
- Deep TMS not FDA-cleared for PTSD; regulatory pathway uncertain.
- Data is retrospective and subject to peer review; may not replicate in prospective trials.
- Competing treatments (e.g., other TMS devices, psychotherapy) may limit market adoption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3318863 |
Track record
24 reports on BWAY
5 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +27.55% at T+60 after the Mar 4, 2026 report. 7 of 10 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Bullish 6/10 No price data
- Nov 10, 20266d ago 6-K Neutral 5/10 Entry $10.67 Now $9.39 −12.00% settles Dec 9
- Nov 2, 202614d ago 6-K Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
- Oct 26, 202621d ago 6-K Neutral 3/10 Entry $11.21 Now $9.39 −16.24% settles Nov 23
- Oct 21, 202626d ago 6-K Neutral 3/10 Entry $11.44 Now $9.39 −17.92% settles Nov 19
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $11.99 Now $9.39 −21.68% due Nov 16
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $11.99 Now $9.39 −21.68% due Nov 16
- Oct 13, 20264w ago 6-K Neutral 4/10 Entry $11.92 to $10.67 Now $9.39 −21.22% ▼ −10.49% −6.88% vs SPY
- Sep 8, 20269w ago 6-K Neutral 4/10 Entry $14.16 to $11.89 Now $9.39 −33.69% ▼ −16.03% −18.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers